Exhibitors Search
Ectosome Inc.
Booth no.
P70
|
Exhibition
|
|KOREA LIFE SCIENCE |
|---|---|
|
Country
|
| |
|
Address
|
|80 Songdogwahak-ro, Yeonsu-gu, Incheon, Republic of Korea |
|
Tel
|
|+82-32-237-6431 |
|
Exhibits
|
| 1) Cell Membrane - Nanodrug Conjugation Platform 2) Stemsome: Stem Cell Membrane-Engineered Liposome and PLGA Drug Delivery Platform |
|
Company Type
|
| Biotech Venture / Startup |
Exhibitor Information
In 2022, we proudly inaugurated the Ectosome Research Center with funding from the National Research Foundation and the Ministry of Science and Technology in South Korea.
You may be wondering: What are ectosomes? How do they differ from exosomes? We invite you to explore our website for detailed answers and a clearer understanding of these concepts.
Our center's foundational philosophy and paramount goal is to discover novel biomarkers and specific or combinatory receptors for the treatment of intractable tumors. This includes challenges posed by metastatic stages and even those cancers resistant to current treatments. Our approach harnesses the potential of stem cell-derived ligands.
Our dedicated team is committed to this mission. The fruits of our research are intended to directly benefit those grappling with some of the most challenging cancers, including pancreatic, lung, and brain cancers, and their metastatic stages.
You may be wondering: What are ectosomes? How do they differ from exosomes? We invite you to explore our website for detailed answers and a clearer understanding of these concepts.
Our center's foundational philosophy and paramount goal is to discover novel biomarkers and specific or combinatory receptors for the treatment of intractable tumors. This includes challenges posed by metastatic stages and even those cancers resistant to current treatments. Our approach harnesses the potential of stem cell-derived ligands.
Our dedicated team is committed to this mission. The fruits of our research are intended to directly benefit those grappling with some of the most challenging cancers, including pancreatic, lung, and brain cancers, and their metastatic stages.
Exhibit Description
Asset 1. Cell membrane - nanodrug conjugation platform _ Pre-Clinical:
Nanodrugs conjugated to stem cells or other migratory cells homing to inflammatory lesions; combines targeted delivery, intrinsic anti-inflammatory activity and near-infrared photothermal therapy
Asset 2. Stemsome: Stem cell membrane-engineered liposome/PLGA DDS _ Pre-Clinical:
Biomimetic nanocarrier using cancer- or inflammation-targeting stem cell membrane vesicles hybridized with liposomes or PLGA nanoparticles; retains endogenous targeting moieties and delivers cytotoxic agents, corticosteroids and nucleic acids
Nanodrugs conjugated to stem cells or other migratory cells homing to inflammatory lesions; combines targeted delivery, intrinsic anti-inflammatory activity and near-infrared photothermal therapy
Asset 2. Stemsome: Stem cell membrane-engineered liposome/PLGA DDS _ Pre-Clinical:
Biomimetic nanocarrier using cancer- or inflammation-targeting stem cell membrane vesicles hybridized with liposomes or PLGA nanoparticles; retains endogenous targeting moieties and delivers cytotoxic agents, corticosteroids and nucleic acids
Individual Exhibit/Technology Introduction (Detailed)
-
Product Name : Cell Membrane - Nanodrug Conjugation PlatformCell-mediated therapeutic delivery platform in which nanotherapeutics are conjugated to stem cells or other migratory cells with intrinsic homing activity toward inflammatory lesions. The platform combines: - Enhanced inflammation-targeted delivery - Cell-mediated anti-inflammatory activity - Near-infrared photothermal therapy - Local delivery of regenerative or disease-modifying agents Target indication: Rheumatoid arthritis, Osteoarthritis The platform has demonstrated effective control of inflammation and promotion of cartilage regeneration in collagen-induced arthritis and monosodium iodoacetate?induced osteoarthritis models. Supporting studies have been published in Advanced Materials in 2024 and Theranostics in 2026.
-
Product Name : Stemsome: Stem Cell Membrane-Engineered Liposome and PLGA Drug Delivery PlatformStemsome is a biomimetic drug delivery platform using disease-targeting stem cell membrane vesicles hybridized with liposomes or integrated into PLGA nanoparticles. Mesenchymal stem cells are engineered or pharmacologically programmed to overexpress disease-targeting membrane proteins, and their membrane vesicles are used to generate multifunctional nanotherapeutics. Stemsome presents multiple endogenous targeting moieties on a single particle, enabling selective accumulation in tumors and inflammatory lesions. It supports cytotoxic agents, corticosteroids, small molecules and nucleic acid therapeutics. Unlike conventional ADCs with limited targeting ligands, its multivalent strategy is designed to improve tissue selectivity and payload delivery while reducing systemic toxicity.
KYUNGYON EXHIBITION CORP.
